
The COPERNICUS study of amivantamab/lazertinib showed lower rates of adverse events and discontinuation with supportive care regimens in patients with EGFR-mutated non–small cell lung cancer.
Metastatic Non-Small Cell Lung Cancer with Alexander Drilon, MD
Case Scenario 2:
SR is a 58 year-old female, former smoker 20 PPY (stopped smoking 5 years ago), presents with cough and SOB. She experienced an unintended 10 lb weight loss over a 3-month period.
Patient was started on carboplatin/paclitaxel/bevacizumab for 4 cycles. Patient showed partial response and was continued on bevacizumab until progression.



